Abstract: CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.

Abstract: CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.

Abstract: A method of treating a viral infection may include administering a pharmaceutical composition including a renin-angiotensin system (RAS) modulator to a subject in need thereof to mitigate a cellular and organic impact of the viral infection. The mitigation may include inhibiting reactive oxygen species, inhibiting cytokine release, upregulating angiotensin-converting enzyme 2 (ACE2), and/or downregulating angiotensin II receptor type 1 (AT1). The renin-angiotensin system modulator may include various combinations of an angiotensin receptor blocker (ARB), angiotensin (1-7), an HMG-CoA reductase inhibitor, an angiotensin-converting-enzyme (ACE) inhibitor, 3,3?-diindolylmethane (DIM), indole-3-carbinol (I3C), and/or pirfenidone (PFD). In addition, at least one of the angiotensin receptor blocker, the angiotensin (1-7), the HMG-CoA reductase inhibitor, the angiotensin-converting-enzyme inhibitor, 3,3?-diindolylmethane, indole-3-carbinol, or pirfenidone may be linked to an antioxidant.

Abstract: Antibodies and antigen-binding fragments thereof that specifically bind to human DCLK1 protein, hybridomas or other cell lines which express such antibodies and antigen-binding fragments thereof, nucleic acids, vectors, and host cells comprising nucleic acids which encode such antibodies and antigen-binding fragments thereof, and methods of use thereof are disclosed. In at least certain non-limiting embodiments, the antibodies or antigen-binding fragments thereof specifically bind to an epitope within isoform 2 or 4 of DCLK1 protein.

Abstract: CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.

Abstract: Antibodies and antigen-binding fragments thereof that specifically bind to human DCLK1 protein, hybridomas or other cell lines which express such antibodies and antigen-binding fragments thereof, nucleic acids, vectors, and host cells comprising nucleic acids which encode such antibodies and antigen-binding fragments thereof, and methods of use thereof are disclosed. In at least certain non-limiting embodiments, the antibodies or antigen-binding fragments thereof specifically bind to an epitope within isoform 2 or 4 of DCLK1 protein.

Abstract: Primer and/or probe sets and arrays for determining microRNA (miRNA) expression signatures that are specific to doublecortin-like kinase 1 (DCLK1) activity, and methods of their use, are disclosed.